Heather Mascio, DO
Nephrology · Chester, PANPI 1962633610
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 29.5% of the total.
Across 47 payments — averaging $23.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$329
- Calliditas Therapeutics US Inc.$136
- Travere Therapeutics, Inc.$108
- Bayer$68
- Novo Nordisk$55
- Mallinckrodt Hospital Products Inc.$50
- plus $371 from 11 others
Across 23 payments — averaging $29,143 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$391K
- Boehringer Ingelheim Pharma GmbH & Co.kg$180K
- Boehringer Ingelheim International GmbH$99K
What the payments were for
- Food & beverage$1,09698%
- Education$202%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 11 | $329 |
| Calliditas Therapeutics US Inc. | 5 | $136 |
| Travere Therapeutics, Inc. | 6 | $108 |
| Bayer | 3 | $68 |
| Novo Nordisk | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Amgen | 2 | $45 |
| Vifor Pharma, Inc. | 2 | $44 |
| Novartis | 2 | $41 |
| GSK | 2 | $38 |
| OPKO Pharmaceuticals, LLC | 2 | $33 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| Ardelyx, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $17 |
How this compares
$1,117 in reported general payments places this provider in the 60th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 198 | $234,211 |
| FarxigaDapagliflozin Propanediol | 196 | $218,805 |
| VelphoroSucroferric Oxyhydroxide | 14 | $48,304 |
| KerendiaFinerenone | 40 | $33,467 |
| VeltassaPatiromer Calcium Sorbitex | 12 | $15,215 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $13,925 |
| DapagliflozinDapagliflozin Propanediol | 11 | $11,670 |
| Sevelamer Carbonate | 31 | $11,376 |
| Lanthanum Carbonate | 11 | $10,545 |
| Calcium Acetate | 71 | $6,436 |
| Nifedipine ErNifedipine | 64 | $3,596 |
| Losartan Potassium | 245 | $3,353 |
| Midodrine Hcl | 50 | $2,875 |
| Calcitriol | 156 | $2,389 |
| Hydralazine Hcl | 80 | $1,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29 | $234,211198 claims |
| AstraZenecaFarxiga, Lokelma | $329 | $232,730209 claims |
| BayerKerendia | $68 | $33,46740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Chester
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.